TY  - GEN
AU  - Okimoto,Ross A
AU  - Lin,Luping
AU  - Olivas,Victor
AU  - Chan,Elton
AU  - Markegard,Evan
AU  - Rymar,Andrey
AU  - Neel,Dana
AU  - Chen,Xiao
AU  - Hemmati,Golzar
AU  - Bollag,Gideon
AU  - Bivona,Trever G
TI  - Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer
SN  - 1091-6490
PY  - 2018///0330
KW  - Animals
KW  - Antineoplastic Agents
KW  - pharmacology
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cell Line, Tumor
KW  - Drug Resistance, Neoplasm
KW  - drug effects
KW  - Enzyme Activation
KW  - Female
KW  - Gene Knockdown Techniques
KW  - Heterocyclic Compounds, 2-Ring
KW  - adverse effects
KW  - Humans
KW  - Lung Neoplasms
KW  - drug therapy
KW  - MAP Kinase Signaling System
KW  - Mechanistic Target of Rapamycin Complex 1
KW  - metabolism
KW  - Mice, SCID
KW  - Mutation
KW  - genetics
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Mas
KW  - Proto-Oncogene Proteins B-raf
KW  - antagonists & inhibitors
KW  - Sulfonamides
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1073/pnas.1610456113
ER  -